Navigation Links
Cynvenio Announces New LiquidBiopsy Test for PD-L1 Expression in Lung Cancer
Date:8/8/2017

Cynvenio Biosystems, Inc. a leader in liquid biopsy technology for cancer research and personalized medicine, today announced the launch of its second generation PD-L1 expression test. The new blood test offers improved analytic performance over the company’s first generation PD-L1 test, enabling highly sensitive and specific profiling and monitoring of PD-L1 expression on lung cancer cells recovered from a simple blood draw.

PD-L1 has been detected to some degree in 50 to 90 percent of non-small cell lung cancers (NSCLC)?, making it an important biomarker in immuno-oncology treatment decisions for lung cancer patients. Several checkpoint inhibitor drugs such as Keytruda, Tecentriq, and Opdivo have been recently approved by the FDA for patients expressing PD-L1 on tumor cells as research shows significant clinical benefit.

“PD-L1 is part of an adaptive dynamic pathway which can readily change as cancer progresses. Relying solely on the original PD-L1 status of a primary tumor specimen or biopsy may preclude patients who might otherwise benefit now for immunotherapy,” commented Paul Y. Song, MD, Cynvenio’s Chief Medical Officer. “Our LiquidBiopsy test allows for real-time monitoring of PD-L1 status on surviving circulating tumor cell clones to more accurately describe the present biologic state. This should allow for more precise patient selection and better outcomes with PD-1/PD-L1 immunotherapy which has shown great promise in lung cancer.”

“This new PD-L1 test analyzes actual tumor cells and cannot be performed using cell-free or ctDNA,” said Paul Dempsey, PhD, Cynvenio’s Chief Science Officer. “Cynvenio’s automated LiquidBiopsy platform makes this test possible, delivering high quality tumor cells from whole blood for downstream analysis.”

Cynvenio is offering the new PD-L1 test from its CLIA/CAP laboratory in California with a 3-7 day turn-around time. The test is also available to all Cynvenio customers running its LiquidBiopsy platform and workflow. Clinicians or scientists interested in ordering the test can visit http://www.clearidmonitoring.com or http://www.liquidbiopsy.com.

About Cynvenio Biosystems, Inc.

Cynvenio’s liquid biopsy testing technology is leading the way to more affordable and clinically actionable precision medicine strategies for cancer patients.  Among the company’s breakthroughs is its line of ClearID® tests for greatly improved cancer detection and monitoring via a patient-friendly blood draw, and a suite of proprietary, distributable LiquidBiopsy® platforms and consumables for deployment in hospitals and third party diagnostic labs. Cynvenio is based in Westlake Village, California. For more information, please visit http://www.cynvenio.comhttp://www.clearidmonitoring.com and http://www.liquidbiopsy.com.

?Patel SP, Kurzrock R: PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy. Molecular Cancer Therapeutics 2015 Apr 9;14:847–856.

LiquidBiopsy® and ClearID® are registered trademarks of Cynvenio Biosystems, Inc.

Read the full story at http://www.prweb.com/releases/2017/08/prweb14581260.htm.


'/>"/>
Source: PRWeb
Copyright©2017 Vocus, Inc.
All rights reserved


Related biology technology :

1. Cynvenio Announces New Deployment of LiquidBiopsy® System at Leading Cancer Research Center in South Korea
2. Cynvenio Announces ClearID® Commercial Distribution Agreements for Israel, Greece, Argentina and South Korea
3. Cynvenio’s LiquidBiopsy® Platform-Derived Research Data to be Presented at the 2017 ASCO Annual Meeting, June 2-June 6, 2017 in Chicago, Illinois
4. Cynvenio Research Highlights Need for Longitudinal Monitoring of Triple Negative Breast Cancer Patients
5. Cynvenio Releases ClearID® Lung Cancer: a Highly-Targeted Genomic Blood Test for Lung and Thoracic Cancer Patients
6. Cynvenio and TME Research Announce Neoadjuvant Breast Cancer Monitoring Study (NEAT)
7. Cynvenio Releases Two New High Recovery LiquidBiopsy® CTC Capture Kits at 2017 AACR Annual Meeting in Washington, DC.
8. Cynvenio Biosystems Announces Expansion of Payer Network with Addition of Blue Cross Blue Shield of Illinois
9. Cynvenio Offers New Breast Cancer Therapy Finder Application for its ClearID Breast Cancer Genomic Test
10. Cynvenio and CollabRx Announce Partnership for Cancer Molecular Diagnostics
11. Cynvenio Biosystems Receives CLIA Certification for its Genomic Sequencing Laboratory
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/4/2019)... ... January 03, 2019 , ... Calidi ... immunotherapies for cancer, today announced the founding of a scientific and medical advisory ... guidance from key leaders in the Immuno-Oncology field. The founding members of Calidi ...
(Date:12/18/2018)... ... 18, 2018 , ... USDM Life Sciences, the leading risk ... unveiled a completely redesigned website at http://www.usdm.com . The site offers improved ... valued clients and business partners. , The website has a revamped ...
(Date:12/13/2018)... ... December 12, 2018 , ... Helping conclude Healthy Aging Month ... and slim hearing aid within its Vision and Hearing campaign that sets out to ... Studies show that despite continued efforts to destigmatize hearing aids over the years, 9 ...
(Date:12/5/2018)... ... ... STRmix™ – sophisticated forensic software capable of resolving mixed DNA profiles previously ... Wyoming man of third-degree sexual assault, a felony punishable by imprisonment for up to ... the couch cushions on which the sexual assault was alleged to have taken place. ...
Breaking Biology Technology:
(Date:12/19/2018)... ... 2018 , ... NDA Partners Chairman Carl Peck, MD, announced today that ... for Devices and Radiological Health (CDRH), has been appointed a Partner in the firm. ... she has more than 25 years of regulatory experience. In addition to her FDA ...
(Date:12/18/2018)... , ... December 18, 2018 , ... ... effectively incorporated artificial intelligence into client marketing. The technology has been effective at ... R3 Stem Cell has been working with clients nationwide on patient acquisition marketing ...
(Date:12/14/2018)... ... December 14, 2018 , ... ... 9,703,929 entitled “Method and System for Microbiome-Derived Diagnostics and Therapeutics” by the US ... October 21, 2014. The patent is an invention by uBiome collaborators Dr. Zachary ...
Breaking Biology News(10 mins):